University of Wisconsin, Madison

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Wisconsin, Madison sits in the top decile of US sponsors by registered trial count (#31 of 15,742 sponsors by registered trial count).

1,039 total trials 151 currently recruiting 712 completed early-phase tilt top decile by trial count

University of Wisconsin, Madison: 1,039 sponsored US clinical trials, 151 recruiting.

University of Wisconsin, Madison sponsors 1,039 registered US clinical trials on ClinicalTrials.gov, 151 of them currently recruiting, and 712 completed. 98 of these trials are in Phase 3-4 (later-stage) and 251 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 10 trials.

Top-decile sponsor footprint

University of Wisconsin, Madison ranks in the top decile of sponsors by registered trial count (#31 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

712 of 824 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,039 total, page 20 of 21

COMPLETED Phase 1

Joint Injections for Osteoarthritic Knee Pain

NCT00085722

COMPLETED

Virtual Colonoscopy (VC) for Primary Colorectal Screening

NCT00204867

COMPLETED NA

Propofol Versus Propofol-Fentanyl as Sedation For Lumbar Puncture in Children With Acute Leukemia/Lymphoma

NCT00214370

COMPLETED NA

Rigid Versus Flexible Cystoscopy in Women

NCT00214045

COMPLETED Phase 1

Organ Preservation Media Investigation

NCT00225472

COMPLETED Phase 1

Hypofractionated Radiotherapy for Lung Cancer

NCT00214123

COMPLETED

Optimizing Cardiac Resynchronization

NCT00205192

COMPLETED

Determination of Fraction Size Equivalent Dose (FED) Levels for Intracranial Conformal Avoidance Radiotherapy

NCT00214175

TERMINATED Phase 1

Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation

NCT00167661

COMPLETED Phase 2

Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer

NCT00205322

COMPLETED NA

Preoperative Preparation for Children

NCT00205244

COMPLETED Phase 2

Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

NCT00581919

COMPLETED Phase 4

Glutamine Popsicles in Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients

NCT00204958

COMPLETED Phase 1

NM404 as an Imaging Agent in Patients With NSCLC

NCT00582283

COMPLETED NA

Cardiac Water and Fluoromethane Cardiac PET

NCT00205127

COMPLETED NA

Free Test Strips and Blood Glucose Control

NCT00205335

COMPLETED NA

Disseminated Endometrial Cancer Cells During Sonohysterography

NCT00205023

COMPLETED Phase 3

Patient-Centered Advance Care Planning

NCT00204802

TERMINATED NA

Quantifying Effects of Treatment of Pediatric Dysphonia

NCT00237679

COMPLETED NA

Dane County Safety Assessment for Elders (SAFE) Research Study

NCT00205114

COMPLETED Phase 1

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

NCT00078559

COMPLETED

Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children

NCT00593918

COMPLETED NA

The Effect of Salmeterol on Eosinophil (EOS) Function

NCT00214019

COMPLETED Phase 2

Family Preparation Study For Withdrawal of Mechanical Ventilation From Their Family Member

NCT00214344

COMPLETED

Laparoscopic Sentinel Lymph Node Localization in Operable Cervix Cancer

NCT00205010

COMPLETED Phase 3

Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)

NCT00065715

COMPLETED NA

Component and Couple Analysis of Cancer Communications

NCT00468741

COMPLETED NA

Mentor Integration Study

NCT00468468

COMPLETED NA

Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection

NCT00205283

TERMINATED Phase 2

Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer

NCT00582790

COMPLETED Phase 1

Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects

NCT00204893

COMPLETED

Quality of Life (QOL) Following Parathyroid Surgery

NCT00205452

COMPLETED NA

Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation

NCT00214201

COMPLETED Phase 2

Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer

NCT00064012

COMPLETED Phase 2

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

NCT00582556

COMPLETED

Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy

NCT00214331

COMPLETED

fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease

NCT00478491

COMPLETED Phase 4

Enteral Glutamine in Neurologically-injured Patients

NCT00204971

COMPLETED

Airway IgA: Respiratory Tract IgA Levels in Critically Ill Intubated Patients

NCT00205309

COMPLETED Phase 1

Phase I/II Hypofractionated Radiotherapy for Prostate Cancer

NCT00214097

COMPLETED Phase 1

Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

NCT00049712

COMPLETED Phase 2

Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT00052832

TERMINATED

Surveillance For New Lung Primaries

NCT00205413

TERMINATED NA

Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix

NCT00204997

COMPLETED

The Use of Shunt Tap in Assessing Ventriculoperitoneal (VP) Shunt Malfunction

NCT00205088

COMPLETED Phase 2

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

NCT00214058

COMPLETED NA

Brain Imaging Techniques That Predict Antidepressant Responsiveness

NCT00909155

COMPLETED Phase 2

Horse Chestnut Seed Extract for Lymphedema

NCT00213928

COMPLETED Phase 2

Pycnogenol for the Treatment of Lymphedema

NCT00214032

COMPLETED NA

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

NCT00205231

← Previous Page 20 of 21 Next →

Phase Distribution

PhaseTrial count
Phase 1 109
Phase 2 142
Phase 3 19
Phase 4 79

What is open in the University of Wisconsin, Madison pipeline

151 recruiting of 1,039 indexed (15% open); 712 completed (69%).

Phase mix: 98 late (III/IV) vs 251 early (I/II) (early-phase heavy).

Top condition: Healthy (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Wisconsin, Madison: open-pipeline peers nationwide

Peers matched on 1,039 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

University of Wisconsin, Madison sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 6%8%10%12%14%16% Total trials Recruiting share University of Wisconsin, MadisonUniversity of WashingtonBristol-Myers SquibbUniversity of FloridaUniversity of North Carolina, Chapel HillMasonic Cancer Center, University of MinnesotaModernaTXUnited States Naval Medical Center, San DiegoThe Cleveland Clinic
University of Wisconsin, Madison sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Wisconsin, Madison sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,039 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this University of Wisconsin, Madison page

1,039 registered trials is a research-attention snapshot, not an endorsement of University of Wisconsin, Madison or any single study.

  • 151 of University of Wisconsin, Madison's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition University of Wisconsin, Madison studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Wisconsin, Madison pipeline card: 1,039 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.